OBJECTIVE: The coagulation and inflammatory cascades may be linked in the pathogenesis of acute lung injury and acute respiratory distress syndrome. However, direct evidence for the contribution of abnormalities in coagulation and fibrinolysis proteins to outcomes in patients with acute lung injury/acute respiratory distress syndrome is lacking. DESIGN: Retrospective measurement of plasma levels of protein C and plasminogen activator inhibitor-1 in plasma samples that were collected prospectively as part of a large multicenter clinical trial. The primary outcome was hospital mortality. To evaluate the potential additive value of abnormalities of these biomarkers, the excess relative risk of death was calculated for each combination of quartiles of protein-C and plasminogen activator inhibitor-1 levels. SETTING: Ten university medical centers. PATIENTS: The study included 779 patients from a multicenter clinical trial of a protective ventilatory strategy in acute lung injury/acute respiratory distress syndrome and 99 patients with acute cardiogenic pulmonary edema, as well as ten normal controls. MEASUREMENTS AND MAIN RESULTS: Compared with plasma from controls and patients with acute cardiogenic pulmonary edema, baseline protein-C levels were low and baseline plasminogen activator inhibitor-1 levels were elevated in acute lung injury/acute respiratory distress syndrome. By multivariate analysis, lower protein C and higher plasminogen activator inhibitor-1 were strong independent predictors of mortality, and ventilator-free and organ-failure-free days. Plasminogen activator inhibitor-1 and protein C had a synergistic interaction for the risk of death. CONCLUSIONS: Early acute lung injury/acute respiratory distress syndrome is characterized by decreased plasma levels of protein C and increased plasma levels of plasminogen activator inhibitor-1 that are independent risk factors for mortality and adverse clinical outcomes. Measurement of plasminogen activator inhibitor-1 and protein-C levels may be useful to identify those at highest risk of adverse clinical outcomes for the development of new therapies.
OBJECTIVE: The coagulation and inflammatory cascades may be linked in the pathogenesis of acute lung injury and acute respiratory distress syndrome. However, direct evidence for the contribution of abnormalities in coagulation and fibrinolysis proteins to outcomes in patients with acute lung injury/acute respiratory distress syndrome is lacking. DESIGN: Retrospective measurement of plasma levels of protein C and plasminogen activator inhibitor-1 in plasma samples that were collected prospectively as part of a large multicenter clinical trial. The primary outcome was hospital mortality. To evaluate the potential additive value of abnormalities of these biomarkers, the excess relative risk of death was calculated for each combination of quartiles of protein-C and plasminogen activator inhibitor-1 levels. SETTING: Ten university medical centers. PATIENTS: The study included 779 patients from a multicenter clinical trial of a protective ventilatory strategy in acute lung injury/acute respiratory distress syndrome and 99 patients with acute cardiogenic pulmonary edema, as well as ten normal controls. MEASUREMENTS AND MAIN RESULTS: Compared with plasma from controls and patients with acute cardiogenic pulmonary edema, baseline protein-C levels were low and baseline plasminogen activator inhibitor-1 levels were elevated in acute lung injury/acute respiratory distress syndrome. By multivariate analysis, lower protein C and higher plasminogen activator inhibitor-1 were strong independent predictors of mortality, and ventilator-free and organ-failure-free days. Plasminogen activator inhibitor-1 and protein C had a synergistic interaction for the risk of death. CONCLUSIONS: Early acute lung injury/acute respiratory distress syndrome is characterized by decreased plasma levels of protein C and increased plasma levels of plasminogen activator inhibitor-1 that are independent risk factors for mortality and adverse clinical outcomes. Measurement of plasminogen activator inhibitor-1 and protein-C levels may be useful to identify those at highest risk of adverse clinical outcomes for the development of new therapies.
Authors: G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg Journal: Am J Respir Crit Care Med Date: 1994-03 Impact factor: 21.405
Authors: James L Januzzi; Carlos A Camargo; Saif Anwaruddin; Aaron L Baggish; Annabel A Chen; Daniel G Krauser; Roderick Tung; Renee Cameron; J Tobias Nagurney; Claudia U Chae; Donald M Lloyd-Jones; David F Brown; Stacy Foran-Melanson; Patrick M Sluss; Elizabeth Lee-Lewandrowski; Kent B Lewandrowski Journal: Am J Cardiol Date: 2005-04-15 Impact factor: 2.778
Authors: K Markus Pelkonen; Ulla Wartiovaara-Kautto; Markku S Nieminen; Kirsi Ahonen; Juha Sinisalo Journal: Blood Coagul Fibrinolysis Date: 2005-06 Impact factor: 1.276
Authors: S Idell; K Gonzalez; H Bradford; C K MacArthur; A M Fein; R J Maunder; J G Garcia; D E Griffith; J Weiland; T R Martin Journal: Am Rev Respir Dis Date: 1987-12
Authors: Harold R Collard; Carolyn S Calfee; Paul J Wolters; Jin Woo Song; Sang-Bum Hong; Sandra Brady; Akitoshi Ishizaka; Kirk D Jones; Talmadge E King; Michael A Matthay; Dong Soon Kim Journal: Am J Physiol Lung Cell Mol Physiol Date: 2010-04-23 Impact factor: 5.464
Authors: Chau-Chyun Sheu; Michelle N Gong; Rihong Zhai; Feng Chen; Ednan K Bajwa; Peter F Clardy; Diana C Gallagher; B Taylor Thompson; David C Christiani Journal: Chest Date: 2010-05-27 Impact factor: 9.410
Authors: John Arcaroli; Jeff Sankoff; Nianjun Liu; David B Allison; James Maloney; Edward Abraham Journal: Intensive Care Med Date: 2007-11-10 Impact factor: 17.440
Authors: Krishnan Raghavendran; Bruce A Davidson; Alan D Hutson; Jadwiga D Helinski; Scott R Nodzo; Robert H Notter; Paul R Knight Journal: J Trauma Date: 2009-12
Authors: Abigail R Cannon; Niya L Morris; Adam M Hammer; Brenda Curtis; Daniel G Remick; Samantha M Yeligar; Lauren Poole; Ellen L Burnham; Todd A Wyatt; Patricia E Molina; Kaku So-Armah; Trinidad Cisneros; Guoshun Wang; Charles H Lang; Pranoti Mandrekar; Elizabeth J Kovacs; Mashkoor A Choudhry Journal: Alcohol Date: 2016-07-25 Impact factor: 2.405
Authors: Kathleen D Liu; Joseph Levitt; Hanjing Zhuo; Richard H Kallet; Sandra Brady; Jay Steingrub; Mark Tidswell; Mark D Siegel; Graciela Soto; Michael W Peterson; Mark S Chesnutt; Charles Phillips; Ann Weinacker; B Taylor Thompson; Mark D Eisner; Michael A Matthay Journal: Am J Respir Crit Care Med Date: 2008-06-19 Impact factor: 21.405